ProfileGDS5678 / 1446845_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 55% 51% 51% 49% 51% 58% 62% 51% 50% 50% 51% 50% 52% 51% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.4065355
GSM967853U87-EV human glioblastoma xenograft - Control 23.2349151
GSM967854U87-EV human glioblastoma xenograft - Control 33.2356551
GSM967855U87-EV human glioblastoma xenograft - Control 43.1182149
GSM967856U87-EV human glioblastoma xenograft - Control 53.1696151
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.5747558
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.7679562
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.2146451
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.1918450
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.1930950
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.2281551
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.1657450
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.2641552
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.2374751